CircRNA Synthesis Market Size, Share and Trends 2025 to 2034

CircRNA Synthesis Market Size and Forecast 2025 to 2034

The global circRNA synthesis market size was estimated at USD 184.83 million in 2024 and is predicted to increase from USD 214.22 million in 2025 to approximately USD 808.36 million by 2034, expanding at a CAGR of 15.90% from 2025 to 2034. The market growth is attributed to increasing investment in RNA-based therapeutics and expanding applications in disease diagnostics and drug development.

CircRNA Synthesis Market Key Takeaways

• North America dominated the global market with a largest share of 46% in 2024.
• Asia Pacific is projected to host the fastest-growing market during the forecast period.
• By product and services, the reagents and kits segment captured the biggest market of 48% in 2024.
• By product and services, the services segment is expected to grow at the fastest CAGR during the forecast period. 
• By application, the therapeutics development segment accounted for a considerable share of 64% in 2024.
• By application, the drug discovery segment is anticipated to grow with the highest CAGR during the studied years.  
• By end user, the pharmaceutical and biotechnology companies segment contributed the highest market of 60% in 2024. 
• By end user, the academic and research institutes segment is projected to expand rapidly during the forecast period.

Impact of Artificial Intelligence on RNA Synthesis Processes

The circRNA synthesis industry receives substantial advancements through artificial intelligence (AI) which enhances research methods, data speed, and precise sequence design. Programmed algorithms through artificial intelligence enable researchers to design sequences that lead to better and more functional circular RNA structures with increased operational speed. The implementation of machine learning models helps identify the best synthesis conditions simultaneously preventing both mistakes and unnecessary resource consumption. Furthermore, AI-driven analytics also refine biomarker discovery, supporting advancements in disease diagnostics and therapeutic development.

U.S. CircRNA Synthesis Market Size and Growth 2025 to 2034

The U.S. circRNA synthesis market size was exhibited at USD 63.77 million in 2024 and is projected to be worth around USD 283. million by 2034, growing at a CAGR of 16.10% from 2025 to 2034.

North America led the circRNA synthesis market, capturing the largest share in 2023, due to the extensive biomedical funding for research and development in the region. The United States leads all other regions through investments totaling USD 15.4 million over three years between the NIH collaboration with NSF for RNA research, according to the 2024 NHGRI report.

This funding program demonstrates that the region backs the development of RNA-based technologies with a special focus on circRNA research. Moreover, the region's National Institutes of Health maintains its commitment to biomedical research by exhibiting rising budget allocations. The market leadership position of North America has intensified due to substantial circRNA research investment commitments.
The Asia Pacific is expected to grow at the fastest rate in the circRNA synthesis market. China has manifested a powerful research and development investment drive by spending RMB 3.6 trillion ($496 billion) which represents 2.64% of its GDP during 2024.  The significant Chinese financial commitment to science makes the country a world leader in research publication, as it produces more academic papers than any other nation.

The regional demand for circRNA synthesis is expected to expand due to government-backed scientific research promotion along with escalating biotechnology startup establishment. The collaboration between Asian research institutions and pharmaceutical companies worldwide pushes forward both circRNA therapeutic development and extends market growth in the coming years.

Market Overview

The growth in the circular RNA (circRNA) synthesis market is primarily driven by applications of circRNAs in both therapeutic development and disease diagnostic fields. The distinctive features of circRNAs make these molecules promising components for diagnostic biomarkers and therapeutic solutions for medical treatment. The market development has gained with recent advancements in in vitro synthesis methods. A research paper in Frontiers in Bioengineering and Biotechnology demonstrated an accurate and effective method for making long-fragment circRNAs by using a group I intron ribozyme. The market for circRNA synthesis production expands due to the convergence of technological innovations with mounting interest in RNA-based therapeutic development.

CircRNA Synthesis Market Growth Factors

• Expanding research in epi transcriptomics is expected to increase demand for advanced circRNA synthesis methods, driving market growth.
• Advancements in high-throughput RNA sequencing technologies are anticipated to improve circRNA identification and structural analysis, supporting market expansion.
• Growing demand for personalized medicine is projected to accelerate the adoption of circRNA-based therapeutics, increasing investment in synthesis technologies.
• Rising focus on synthetic biology and RNA therapeutics is likely to fuel innovations in circRNA synthesis, strengthening commercial applications.
• Artificial intelligence and machine learning integration in RNA research are expected to enhance circRNA design efficiency, boosting demand for optimized synthesis platforms.
• Increasing collaborations between biopharmaceutical companies and research institutions are anticipated to accelerate clinical translation, expanding the market for custom circRNA synthesis services.
• Expansion of CRISPR and RNA-editing technologies is projected to improve circRNA engineering, increasing its use in drug discovery and gene therapy applications.

Market Scope

Market Dynamics

Drivers

Growing Demand for Next-Generation RNA Molecules

Growing demand for next-generation RNA molecules is anticipated to boost the circRNA synthesis market in the coming years. The rising market need for next-generation RNA molecules creates favorable conditions for developing breakthrough methods to synthesize circular RNA (circRNA). According to the 2025 NIH report, extensive studies have shown that circRNA vaccines demonstrate remarkable stability, provoke strong immune responses, and lead to the production of substantial amounts of neutralizing antibodies. This makes circRNA valuable for developing treatments against genetic conditions neurodegenerative diseases and viral infections. Bioinformatics, alongside structural modeling methods, have improved the precision rate of circRNA construction, which leads to enhanced functional results.

The World Health Organization International Clinical Trials Registry Platform shows an increase in RNA-based therapy clinical trials from 2022 to 2023, which indicates advancing interest in RNA therapeutic applications. Furthermore, the synthetic biology and gene editing technologies, together with their rapid development, have made circRNA accessible for biomedical uses which enhances its clinical value in modern therapeutic interventions. 

Restraint

Hampered Large-Scale Production Due to High Synthesis Costs

Hamper large-scale production due to high synthesis costs is anticipated to limit the expansion of circRNA-based applications. Advanced enzymatic reactions in combination with sophisticated purification strategies drive up the production costs of synthesis protocols. The financial requirements for specialized reagents together with high-throughput sequencing systems and custom bioinformatics tools make circRNA exploration inaccessible for small research institutions and emerging biotech firms. The manufacturing scalability faces obstacles due to present limitations in developing economical methods to produce large-scale high-purity circRNA for commercial purposes.

Furthermore, the insufficient financial support for small-scale enterprises creates hurdles for adopting new technologies as it hinders the process of commercializing circRNA-based therapeutic products. The market experiences growth constraints because of the high costs required for regulatory clearances and with the quality control requirements.

Opportunity

Growing Applications in Neurological Disorders

Growing applications in neurological disorders are anticipated to expand the research scope of circRNA synthesis, which further creates immense opportunities for the players competing in the market. As per the National Library of Medicine 2023 report, studies demonstrate synaptic circRNAs involved in brain disorders have reached 61% of total circRNA while 4,834 circRNA variants were found to be cell-type specific within neurons that control movement or mood, and memory or language functions. Research teams investigate how circRNAs regulate neuronal differentiation while studying synaptic plasticity phenomena, which strengthens their application in regenerative medicine.

High-quality circRNA synthesis has become increasingly important, as RNA-based therapies show potential for treating both stroke and traumatic brain injuries. Pharmaceutical entities join hands with academic research centers to enhance drug development speed and thereby boost funding for neuro-specific circRNA studies.

• The Shanghai Science and Technology Commission granted Byterna 2 million RMB in 2024 to fund its investigative research on circular RNA AI design and chemical modification technology, which solves issues in developing circRNA therapeutic strategies. The research field demonstrates growing interest in using circRNA to deal with neurological disorders, which further fuels the market.

Product and Services Insights

Reagents & Kits segment dominated the circRNA synthesis market during the forecasting period, due to the technical advances that improve reaction protocols for both buffer optimization and RNA circularization alongside user-friendly kit design developments. The implementation of improved enzymes and optimized production settings enables greater efficiency in laboratory chemical processes, thereby increasing overall laboratory productivity.

The National Institutes of Health released a 2025 report revealing that modern RNA reagent developments have expedited new RNA-cavitating treatments discovery, which increases the necessity for first-class kits. Furthermore, the organizations that develop automated reagent preparation systems and scalable synthesis solutions position themselves better in the market since they serve synthetic biology applications with high-throughput requirements.

The services segment is projected to grow at the fastest rate in the market in the future years, as circRNA research now extends beyond therapeutic boundaries, specialized services that specialize in synthesis, modification, and analysis become a necessity. The partnership of pharmaceutical companies with academic institutions speeds up drug discovery operations, which strengthens the market demand for these specialized services.

• In 2023, the U.S. Food and Drug Administration dictated through its announcement that RNA-based treatments need strict synthesis processes along with rigorous quality control standards, thus driving researchers toward expert service providers. Furthermore, the segment’s projected growth continues to strengthen as investors increase their stake in complete circRNA synthesis solutions starting with sequence design through large-scale production.

Application Insights

The therapeutics development segment held the largest share in the circRNA synthesis market during the forecasting period, due to the expanding recognition of circular RNAs as having therapeutic potential for various medical conditions. Current scientific studies have confirmed that circRNAs act as important controllers of gene networks and demonstrate great potential for serving as new therapeutic approaches. These features enable circRNAs to resist exonuclease degradation better than linear RNAs, which creates beneficial conditions for developing effective therapies. Biotechnology companies partnered to accelerate clinical application development of circRNA science, which solidified the leading role of therapeutics development as a segment.

• In 2023, Esperovax, an innovative developer of oral mRNA biologics, partnered with Ginkgo Bioworks, a leader in cell programming and biosecurity. Together, they develop circular RNAs (circRNAs) for various therapeutic applications. Initially, their collaboration focus on creating circRNAs designed to specifically target colorectal cancer by inducing cell death only in cancerous cells.

Drug discovery sub-segment is projected to grow at the fastest rate in the market in the coming years. The exclusive characteristics of circRNAs including their microRNA sponge effects alongside their interactions with RNA-binding proteins drive important understanding regarding disease processes and therapeutic objectives. Technology improvements in high-throughput sequencing enable researchers to better discover and study circRNAs, thereby making the molecules more useful for drug development research. Furthermore, the pharmaceutical industry involves significant investment in circRNA research because scientists expect these discoveries to decrease drug development times to produce more effective medical treatments. 

End-use Insights

The pharmaceutical & biotechnology segment dominated the circRNA synthesis market. These corporations identified circRNAs' therapeutic applications, which turned into expanded studies for creating new treatment modalities containing circRNAs. The sector grew stronger through business and research partnerships that contributed to turning circRNA findings into medical applications. Pharmaceutical and biotechnology firms grasped the fundamental function of RNA therapeutic pipeline expansion for advancing circRNA synthesis technologies through their strategic plans. The circRNA-based therapeutic development by Orna Therapeutics together with Circio demonstrates an innovative approach to address unaddressed clinical necessities for mRNA vaccine advancements and targeted cancer treatment. 

The academic & research institutes sub-segment is projected to grow rapidly in the circRNA synthesis market in the coming years. Academic and research institutions have a promising outlook for driving essential studies about circRNA generation and performance, and therapeutic capabilities, which expands knowledge about circRNA operations. Government grants together with funding programs enable extensive circRNA research projects to take place in academic institutions. Research England devoted large sums of money from its 2024 to 2025 budget plan for both academic years to upgrade research facilities and boost innovation capacities at higher education institutions. Furthermore, the academic-industry partnerships enable basic research discoveries to advance toward medical applications, thus driving innovative therapy options based on circRNA technology.

CircRNA Synthesis Market Companies

• Amerigo Scientific
• Applied Biological Materials Inc.
• BOC Sciences
• Creative Biogene.
• Creative Biolabs
• GeneCopoeia, Inc.
• GenScript
• Guangzhou Geneseed Biotech. Co., Ltd.
• LGC Biosearch Technologies
• SBS Genetech

Recent Developments

• In September 2024, the Mass General Brigham Gene and Cell Therapy Institute (GCTI) announced the launch of the RNA Therapeutics Core, a state-of-the-art facility dedicated to advancing the use of RNA technologies within and beyond the Mass General Brigham research ecosystem. This pioneering Core aims to accelerate the exploration of novel therapeutic targets to effectively translate RNA-based medicines into clinical practice by utilizing advanced RNA vectors and delivery systems.
• In May 2024, GenScript Biotech Corporation, a global leader in life science research tools and services, announced the expansion of its in vitro transcription (IVT) RNA synthesis portfolio to include self-amplifying RNA (saRNA). This innovative addition solidifies GenScript's position at the forefront of IVT RNA technology, providing researchers with a new format for applications such as vaccines, cancer immunotherapy, and gene or cell therapy development.
• In September 2022, EnPlusOne Biosciences, Inc., a biotechnology company focused on harnessing the power of enzymes to synthesize RNA oligonucleotides, formally launched with USD 12 million in seed financing. This funding round was led by Northpond Ventures, with participation from Breakout Ventures, Coatue, and angel investors. The financing supports the continued development and scaling of the company’s proprietary ezRNA™ synthesis platform, aligning with its mission to enable next-generation solutions for emerging RNA therapeutics.
• In May 2024, Johns Hopkins University, which has significant expertise in RNA sciences and therapeutic development, announced a new academic collaboration with TriLink BioTechnologies, part of Maravai LifeSciences. This partnership aims to accelerate transformational research in RNA therapeutics and discovery. It includes the establishment of a new center in the university’s Whiting School of Engineering and access to TriLink’s leading RNA synthesis technology, which expedites research and therapeutic development.

Latest Announcements by Industry Leaders

• In February 2025, Roche announced today the launch of its proprietary breakthrough technology, sequencing by expansion (SBX), which establishes a new category in next-generation sequencing. The SBX chemistry, combined with an innovative sensor module, enables ultra-rapid, high-throughput sequencing that is both flexible and scalable for a wide range of applications.

Segments Covered in the Report

By Product & Service

• Instruments
• Reagents & Kits
• Services

By Application

• Drug Discovery
• Therapeutics Development
• Other

By End Use

• Academic & Research Institutes
• Pharmaceutical & Biotechnology Companies
• Others

By Geography

• North America
• Europe
• Asia Pacific
• Latin America
• Middle East & Africa